Inclusion criteria | |
---|---|
1. | Both gender between the ages of 18-69 years, eligible for study through screening test prior to the enrolment. |
2. | Able and willing to perform the study protocol and participate throughout the entire trial period(Screening, baseline, 3, 6 weeks, follow up(if needed)). |
3. | Participants who understood the risks and benefits of the study and signed a written informed consent. |
4. | Among individuals not under diabetes mellitus treatment, whose random glucose concentration is 110~250 mg/dL measured with Accu-Chek®(Roche, Germany) glucometer within 3 weeks prior to participation. |
4.1. | fasting plasma glucose concentration is 100-190 mg/dL or |
4.2. | 2- hour plasma glucose concentration* is 130-250 mg/dL( * venous plasma glucose 2-hour after ingestion of 75 g oral glucose load; DIASOL-S LIQ. [Glucose] Taejoon Pharm.) |